BRIEF published on 01/08/2025 at 14:35, 1 year 3 months ago Health Canada Approves Formycon's Biosimilar FYB202/Otulfi® Healthcare Costs Biosimilar Formycon Ustekinumab Canada Approval
PRESS RELEASE published on 01/08/2025 at 14:30, 1 year 3 months ago Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Formycon and Fresenius Kabi Canada obtain Health Canada's approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Health Canada Approval Biosimilar Formycon Stelara Fresenius Kabi Canada
BRIEF published on 12/11/2024 at 16:31, 1 year 4 months ago Formycon AG Maintains Strong Growth Prospects Amidst Challenging Market Conditions FDA Approval Revenue Decline Formycon AG Biosimilars Stelara Launch
PRESS RELEASE published on 12/11/2024 at 16:26, 1 year 4 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF published on 12/09/2024 at 06:35, 1 year 4 months ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
PRESS RELEASE published on 12/09/2024 at 06:30, 1 year 4 months ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
BRIEF published on 12/05/2024 at 13:00, 1 year 5 months ago Formycon Joins the SDAX of the German Stock Exchange Market Strategy Biosimilars SDAX Formycon German Stock Exchange
PRESS RELEASE published on 12/05/2024 at 12:55, 1 year 5 months ago Formycon joins the SDAX of the German Stock Exchange Formycon AG joins the SDAX of the German Stock Exchange, enhancing share attractiveness and visibility in the capital market. Key milestone in the company's growth strategy Formycon AG Biosimilars Capital Market SDAX German Stock Exchange
BRIEF published on 11/28/2024 at 06:35, 1 year 5 months ago Formycon Reports Continued Growth in 2024 Nine-Month Results Financial Results Market Position FDA Approval Biosimilars Strategic Growth
PRESS RELEASE published on 11/28/2024 at 06:30, 1 year 5 months ago Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes Formycon reports nine-month results for 2024 with operational successes and growth trajectory, including product approvals and new biosimilar candidates Biosimilars Growth Trajectory Formycon Nine-month Results Operational Successes
Published on 05/06/2026 at 09:01, 3 hours 5 minutes ago Apex Widens and Extends Newly Discovered Zone with Significant NdPr Enrichment (>30%)
Published on 05/06/2026 at 02:17, 9 hours 49 minutes ago Troubadour Announces Share Consolidation and Effective Date
Published on 05/06/2026 at 02:00, 10 hours 6 minutes ago Vanta Announces Closing of First Tranche of Private Placement and Debt Settlement
Published on 05/06/2026 at 02:00, 10 hours 6 minutes ago Alset AI Announces Shares for Debt Transaction
Published on 05/06/2026 at 11:38, 28 minutes ago Drägerwerk AG & Co. KGaA: No vote on items 7 and 8 of the agenda at the Annual Shareholders’ Meeting on May 8, 2026 - Cancellation of the separate meeting of preferred shareholders
Published on 05/06/2026 at 10:45, 1 hour 21 minutes ago Thailand Approves $29 Billion Investment Wave as Data Center Demand Surges
Published on 05/06/2026 at 10:00, 2 hours 6 minutes ago 2026 Pacific Ocean International Festival of Rock Balancing and Arts Holds Grand Opening at Qixingtan Scenic Area on May 1st
Published on 05/06/2026 at 10:00, 2 hours 6 minutes ago Mallia Therapeutics Announces Publication and Congress Presentation on Accelerated Wound Healing with sCD83
Published on 05/06/2026 at 10:00, 2 hours 6 minutes ago MAKTEK Eurasia 2026 positions Türkiye as a manufacturing hub
Published on 05/06/2026 at 10:09, 1 hour 57 minutes ago Guillemot Corporation : Information regarding the total number of voting rights and shares 30/04/2026
Published on 05/06/2026 at 08:42, 3 hours 24 minutes ago Disclosure of shares outstanding and voting rights - 06.05.2026
Published on 05/05/2026 at 19:00, 17 hours 6 minutes ago Combined General Meeting of Air Liquide Shareholders of May 5, 2026
Published on 05/05/2026 at 18:03, 18 hours 3 minutes ago Aéroports de Paris SA - Shares and voting rights as of 30 April 2026
